These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 24166094)

  • 21. Crizotinib in the treatment of non--small-cell lung cancer.
    Rothschild SI; Gautschi O
    Clin Lung Cancer; 2013 Sep; 14(5):473-80. PubMed ID: 23790969
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting ALK in neuroblastoma--preclinical and clinical advancements.
    Carpenter EL; Mossé YP
    Nat Rev Clin Oncol; 2012 May; 9(7):391-9. PubMed ID: 22585002
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment.
    Huang D; Kim DW; Kotsakis A; Deng S; Lira P; Ho SN; Lee NV; Vizcarra P; Cao JQ; Christensen JG; Kim TM; Sun JM; Ahn JS; Ahn MJ; Park K; Mao M
    Genomics; 2013 Sep; 102(3):157-62. PubMed ID: 23434628
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Crizotinib: an anaplastic lymphoma kinase inhibitor.
    Gadgeel SM; Bepler G
    Future Oncol; 2011 Aug; 7(8):947-53. PubMed ID: 21823889
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma.
    Krytska K; Ryles HT; Sano R; Raman P; Infarinato NR; Hansel TD; Makena MR; Song MM; Reynolds CP; Mossé YP
    Clin Cancer Res; 2016 Feb; 22(4):948-60. PubMed ID: 26438783
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on-target ALK inhibitors in neuroblastoma.
    Tucker ER; Tall JR; Danielson LS; Gowan S; Jamin Y; Robinson SP; Banerji U; Chesler L
    Mol Oncol; 2017 Aug; 11(8):996-1006. PubMed ID: 28432815
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeted therapy for NSCLC: ALK inhibition.
    Pearson R; Kolesar JM
    J Oncol Pharm Pract; 2012 Jun; 18(2):271-4. PubMed ID: 21844131
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors.
    Ceccon M; Mologni L; Bisson W; Scapozza L; Gambacorti-Passerini C
    Mol Cancer Res; 2013 Feb; 11(2):122-32. PubMed ID: 23239810
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Crizotinib-induced erosive esophagitis in a pediatric patient with neuroblastoma.
    Lubcke N; Van Camp K
    J Oncol Pharm Pract; 2019 Apr; 25(3):724-726. PubMed ID: 29357780
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Promising therapeutic targets in neuroblastoma.
    Matthay KK; George RE; Yu AL
    Clin Cancer Res; 2012 May; 18(10):2740-53. PubMed ID: 22589483
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical feature of anaplastic lymphoma kinase-mutated neuroblastoma.
    Ogura T; Hiyama E; Kamei N; Kamimatsuse A; Ueda Y; Ogura K
    J Pediatr Surg; 2012 Oct; 47(10):1789-96. PubMed ID: 23084186
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Testing for anaplastic lymphoma kinase rearrangement to target crizotinib therapy: oncology, pathology and health economic perspectives.
    Lee JA; Bubendorf L; Stahel R; Peters S
    Expert Rev Anticancer Ther; 2013 May; 13(5):625-36. PubMed ID: 23617353
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining factor of an unfavorable phenotype in primary neuroblastoma.
    Schulte JH; Bachmann HS; Brockmeyer B; Depreter K; Oberthür A; Ackermann S; Kahlert Y; Pajtler K; Theissen J; Westermann F; Vandesompele J; Speleman F; Berthold F; Eggert A; Brors B; Hero B; Schramm A; Fischer M
    Clin Cancer Res; 2011 Aug; 17(15):5082-92. PubMed ID: 21632861
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The preclinical profile of crizotinib for the treatment of non-small-cell lung cancer and other neoplastic disorders.
    Roskoski R
    Expert Opin Drug Discov; 2013 Sep; 8(9):1165-79. PubMed ID: 23805942
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of different ALK mutations in a pair of neuroblastoma cell lines established at diagnosis and relapse.
    Chen L; Humphreys A; Turnbull L; Bellini A; Schleiermacher G; Salwen H; Cohn SL; Bown N; Tweddle DA
    Oncotarget; 2016 Dec; 7(52):87301-87311. PubMed ID: 27888620
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anaplastic lymphoma kinase (ALK) inhibitor response in neuroblastoma is highly correlated with ALK mutation status, ALK mRNA and protein levels.
    Duijkers FA; Gaal J; Meijerink JP; Admiraal P; Pieters R; de Krijger RR; van Noesel MM
    Cell Oncol (Dordr); 2011 Oct; 34(5):409-17. PubMed ID: 21625996
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine.
    Pilotto S; Peretti U; Novello S; Rossi G; Milella M; Giaj Levra M; Ciuffreda L; Massari F; Brunelli M; Tortora G; Bria E
    Expert Opin Pharmacother; 2013 Apr; 14(5):597-608. PubMed ID: 23472711
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Ceritinib in the treatment of an adult patient with advanced neuroblastoma positive to the somatic activating mutation of ALK F1174L.].
    Soto Parra HJ; Noto L; Aiello MM
    Recenti Prog Med; 2020 Dec; 111(12):58e-62e. PubMed ID: 33362184
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice.
    Siaw JT; Wan H; Pfeifer K; Rivera VM; Guan J; Palmer RH; Hallberg B
    Oncotarget; 2016 May; 7(20):29011-22. PubMed ID: 27049722
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ALKoma: a cancer subtype with a shared target.
    Mano H
    Cancer Discov; 2012 Jun; 2(6):495-502. PubMed ID: 22614325
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.